Abstract
The majority of all proteins are modularly built from a limited set of approximately 1,000 structural domains. The knowledge of a common protein fold topology in the ligand-sensing cores of protein domains can be exploited for the design of small-molecule libraries in the development of inhibitors and ligands. Thus, a novel strategy of clustering protein domain cores based exclusively on structure similarity considerations (protein structure similarity clustering, PSSC) has been successfully applied to the development of small-molecule inhibitors of acetylcholinesterase and the 11β-hydroxysteroid dehydrogenases based on the structure of a naturally occurring Cdc25 inhibitor. The efficiency of making use of the scaffolds of natural products as biologically prevalidated starting points for the design of compound libraries is further highlighted by the development of benzopyran-based FXR ligands.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Abreu PM, Branco PS (2003) Natural product-like combinatorial libraries. J Braz Chem Soc 14:675–712
Ajay Walters WP, Murcko MA (1998) Can we learn to distinguish between “drug-like” and “nondrug-like” molecules? J Med. Chem 41:3314–3324
Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B, Abrahmsen L (2002) Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45:1528–1532
Arya P, Joseph R, Chou DTH (2002) Toward high-throughput synthesis of complex natural product-like compounds in the genomics and proteomics age. Chem Biol 9:145–156
Barun O, Sommer S, Waldmann H (2004) Asymmetric solid-phase synthesis of 6,6-spiroketals. Angew Chem Int Ed 43:3195–3199, and references therein
Bogan AA, Cohen FE, Scanlan TS (1998) Natural ligands of nuclear receptors have conserved volumes. Nat Struct Biol 5:679–681
Breinbauer R, Vetter IR, Waldmann H (2002) From protein domains to drug candidates — natural products as guiding principles in the design and synthesis of compound libraries. Angew Chem Int Ed 41:2879–2890
Brohm D, Metzger S, Bhargava A, Muller O, Lieb F, Waldmann H (2002a) Natural products are biologically validated starting points in structural space for compound library development: solid-phase synthesis of dysidiolidederived phosphatase inhibitors. Angew Chem Int Ed 41:307–311
Brohm D, Philippe N, Metzger S, Bhargava A, Muller O, Lieb F, Waldmann H (2002b) Solid-phase synthesis of dysidiolide-derived protein phosphatase inhibitors. J Am Chem Soc 124:13171–13178
Chrousos GP (2004) Is 11beta-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc Natl Acad Sci U S A 101:6329–6330
Claudel T, Sturm E, Kuipers F, Staels B (2004) The farnesoid X receptor: a novel drug target? Expert Opin Investig Drugs 13:1135–1148
Dang ZC, Audinot V, Papapoulos SE, Boutin JA, Lowik C (2003) Peroxisome proliferator-activated receptor gamma (PPAR gamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem 278:962–967
Evans BE, Rittle KE, Bock MG, Dipardo RM, Freidinger RM, Whitter WL, Lundell GF, Veber DF, Anderson PS, Chang RSL et al (1988) Methods for drug discovery — development of potent selective orally effective cholecystokinin antagonists. J Med Chem 31:2235–2246
Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA et al (2003) A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11:1079–1092
Fauman EB, Cogswell JP, Lovejoy B, Rocque WJ, Holmes W, Montana VG, Piwnica-Worms H, Rink MJ, Saper MA (1998) Crystal structure of the catalytic domain of the human cell cycle control phosphatase Cdc25A. Cell 93:617–625
Frye SV (1999) Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chem. Biol 6:R3–R7
Gerlt JA, Babbitt PC (2001) Divergent evolution of enzymatic function: mechanistically diverse superfamilies and functionally distinct suprafamilies. Annu Rev Biochem 70:209–246
Ghose AK, Viswanadhan VN, Wendoloski JJ (1999) A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1:55–68
Golebiowski A, Klopfenstein SR, Portlock DE (2001) Lead compounds discovered from libraries. Curr Opin Chem Biol 5:273–284
Grishin NV (2001) Fold change in evolution of protein structures. J Struct Biol 134:167–185
Gunasekera SP, McCarthy PJ, KellyBorges M, Lobkovsky E, Clardy J (1996) Dysidiolide: a novel protein phosphatase inhibitor from the Caribbean sponge Dysidea etheria de Laubenfels. J Am Chem Soc 118:8759–8760
Holm L, Sander C (1996) The FSSP database: fold classification based on structure-structure alignment of proteins. Nucleic Acids Res 24:206–209
Holm L, Sander C (1997) Dali/FSSP classification of three-dimensional protein folds. Nucleic Acids Res 25:231–234
Ibach B, Haen E (2004) Acetylcholinesterase inhibition in Alzheimer’s disease. Curr Pharm Des 10:231–251
Jacoby E, Schuffenhauer A, Floersheim P (2003) Chemogenomics knowledge-based strategies in drug discovery. Drug News Perspect 16:93–102
Koch MA, Waldmann H (2004) Natural product-derived compound libraries and protein structure similarity as guiding principles for the discovery of drug candidates. In: Kubinyi H, Müller G (eds) Chemogenomics in drug discovery: a medicinal chemistry perspective. Wiley-VCH, Weinheim, pp 377–403
Koch MA, Waldmann H (2005) Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. Drug Discov Today 10:471–483
Koch MA, Breinbauer R, Waldmann H (2003) Protein structure similarity as guiding principle for combinatorial library design. Biol Chem 384:1265–1272
Koch MA, Wittenberg L-O, Basu S, Jeyaraj DA, Gourzoulidou E, Reinecke K, Odermatt A, Waldmann H (2004) Compound library development guided by protein structure similarity clustering and natural product structure. Proc Natl Acad Sci U S A 101:16721–16726
Lee ML, Schneider G (2001) Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. J Comb Chem 3:284–289
Lyon MA, Ducruet AP, Wipf P, Lazo JS (2002) Dual-specificity phosphatases as targets for antineoplastic agents. Nat Rev Drug Discov 1:961–976
Mason JS, Hermsmeier NA (1999) Diversity assessment. Curr Opin Chem Biol 3:342–349
Masuzaki H, Flier JS (2003) Tissue-specific glucocorticoid reactivating enzyme, 11 beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) — a promising drug target for the treatment of metabolic syndrome. Curr Drug Targets Immune Endocr Metabol Disord 3:255–262
Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166–2170
New MI, Wilson RC (1999) Steroid disorders in children: congenital adrenal hyperplasia and apparent mineralocorticoid excess. Proc Natl Acad Sci U S A 96:12790–12797
Nicolaou KC, Pfefferkorn JA, Roecker AJ, Cao GQ, Barluenga S, Mitchell HJ (2000a) Natural product-like combinatorial libraries based on privileged structures 1. General principles and solid-phase synthesis of benzopyrans. J Am Chem. Soc 122:9939–9953
Nicolaou KC, Pfefferkorn JA, Mitchell HJ, Roecker AJ, Barluenga S, Cao GQ, Affleck RL, Lillig JE (2000b) Natural product-like combinatorial libraries based on privileged structures 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using NanoKans and optical encoding. J Am Chem Soc 122:9954–9967
Nicolaou KC, Pfefferkorn JA (2001) Solid phase synthesis of complex natural products and libraries thereof. Biopolymers 60:171–193
Nicolaou KC, Evans RM, Roecker AJ, Hughes R, Downes M, Pfefferkorn JA (2003) Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org Biomol Chem 1:908–920
Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ (2004) Metabolic syndrome without obesity: hepatic overexpression of 11beta-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 101:7088–7093
Pike ACW, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engstrom O, Ljunggren J, Gustafsson JK, Carlquist M (1999) Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J 18:4608–4618
Robinson-Rechavi M, Escriva Garcia H, Laudet V (2003) The nuclear receptor superfamily. J Cell Sci 116:585–586
Ross SA, Gulve EA, Wang M (2004) Chemistry and biochemistry of type 2 diabetes. Chem Rev 104:1255–1282
Russell RB, Sasieni PD, Sternberg MJE (1998) Supersites within superfolds. Binding site similarity in the absence of homology. J Mol Biol 282:903–918
Sadowski J, Kubinyi H (1998) A scoring scheme for discriminating between drugs and nondrugs. J Med Chem 41:3325–3329
Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, Seckl JR (2004) 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci U S A 101:6734–6739
Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L, Silman I (1991) Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253:872–879
Schapira M (2002) Pharmacogenomics opportunities in nuclear receptor targeted cancer therapy. Curr Cancer Drug Targets 2:243–256
Schapira M, Raaka BM, Samuels HH, Abagyan R (2000) Rational discovery of novel nuclear hormone receptor antagonists. Proc Natl Acad Sci U S A 97:1008–1013
Schreiber SL (2000) Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287:1964–1969
Schweizer RA, Atanasov AG, Frey BM, Odermatt A (2003) A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity. Mol Cell Endocrinol 212:41–49
Shindyalov IN, Bourne PE (1998) Protein structure alignment by incremental combinatorial extension (CE) of the optimal path. Protein Eng 11:739–747
Spencer RW (1998) High-throughput screening of historic collections: observations on file size, biological targets, and file diversity. Biotechnol Bioeng 61:61–67
Todd AE, Orengo CA, Thornton JM (1999) Evolution of protein function, from a structural perspective. Curr Opin Chem Biol 3:548–556
Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan YZ, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD (2002) A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296:1703–1706
Van Gaal L, Scheen AJ (2002) Are all glitazones the same? Diabetes Metab Res Rev 18[Suppl 2]:S1–S4
Walker BR, Seckl JR (2003) 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert Opin Ther Targets 7:771–783
Walters WP, Murcko A, Murcko MA (1999) Recognizing molecules with drug-like properties. Curr Opin Chem Biol 3:384–387
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Koch, M.A., Waldmann, H. (2006). Protein Structure Similarity Clustering and Natural Product Structure as Guiding Principles for Chemical Genomics. In: Jaroch, S., Weinmann, H. (eds) Chemical Genomics. Ernst Schering Research Foundation Workshop, vol 58. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-37635-4_7
Download citation
DOI: https://doi.org/10.1007/978-3-540-37635-4_7
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-27865-8
Online ISBN: 978-3-540-37635-4
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)